Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Ujin Pharma Limited distributes solvents, speciality chemicals, acids, monomers, pharmaceutical raw materials and nutraceuticals, and processes solvents and printing chemicals through SSOPL. The proposed IPO pairs a Fresh Issue of up to 11,869,100 equity shares with an OFS of up to 7,282,300 equity shares, and listing is proposed on BSE and NSE. Net Proceeds will fund the conversion of two associate companies into subsidiaries and repay part of the borrowings. Demand from pharmaceuticals, agrochemicals and industrial manufacturing may continue to support the chemical distribution market, as per the D&B Report cited in the DRHP.
The risks warrant equal attention. Thin margins, product and supplier concentration, import exposure and pending legal proceedings, each disclosed in the DRHP, remain the points to watch.
Ujin filled The Draft Red Herring Prospectus (DRHP) describing it as a distributor and supplier of solvents, speciality chemicals, acids, monomers, pharmaceutical raw materials and nutraceuticals.
The company filed its DRHP, dated 22 June 2026, with the Securities and Exchange Board of India (SEBI) for an initial public offering. The Ujin Pharma IPO pairs a Fresh Issue with an Offer for Sale (OFS). Listing is proposed on both BSE and NSE. SMC Capitals Limited and Marwadi Chandarana Intermediaries Brokers Private Limited will manage the book, while KFin Technologies Limited acts as registrar to the offer.
A DRHP carries the details investors typically look for: the business model, operations, promoters, financial record and the risks that come with each. This article draws out the key disclosures in simple terms.
The table below highlights the key details of the public issue available in the DRHP, while the price band, lot size and issue dates are yet to be announced.
| Particulars | Details |
|---|---|
| IPO Type | Book Built Issue |
| IPO Open Date | To be announced |
| IPO Close Date | To be announced |
| Face Value | ₹10 per equity share |
| Price Band | To be announced |
| Lot Size | To be announced |
| Fresh Issue | Up to 11,869,100 equity shares |
| Offer for Sale | Up to 7,282,300 equity shares |
| Total Issue Size | Up to 19,151,400 equity shares |
| Listing Exchange | BSE and NSE |
Two promoter selling shareholders participate in the OFS, each offering up to 3,641,150 equity shares: Jinesh Sheth and Umang Mehta. None of the OFS money reaches the company; it goes to the selling shareholders after offer expenses and taxes are deducted.
The Fresh Issue proceeds carry three named objects. ₹61.72 crore will go towards Altra Agro-Chem Private Limited and ₹21.64 crore towards Altra Pharma-Chem Private Limited, both associate companies, through subscription to equity shares to make them subsidiaries. A further ₹25 crore is earmarked for repayment or pre-payment of certain borrowings, with the balance kept for general corporate purposes. No Pre-IPO Placement is proposed.
Reservation follows the standard Book Built pattern. Qualified Institutional Buyers can take not more than 50% of the net offer, retail individual bidders not less than 35%, and non-institutional bidders not less than 15%. Price band, lot size and subscription dates will follow closer to the opening of the public issue.
The business traces back to a partnership firm named Ujin Pharma Chem, formed under a deed dated 5 May 2005. The firm became Ujin Pharma Private Limited on 21 May 2024, and a fresh certificate of incorporation dated 15 May 2025 marked its conversion into a public limited company. The registered office sits at Vidyavihar West, Mumbai, Maharashtra.
The DRHP names three promoters: Jinesh Rasiklal Sheth, Umang Ketan Mehta and Neha Umang Mehta, with a pre-issue promoter holding of 98.50%. Headcount stood at 73 employees on a consolidated level as of 31 March 2026.
Ujin Pharma runs two verticals. The larger one is chemical distribution, built on more than two decades of experience carried over from the predecessor firm. The newer vertical is value-added chemical processing through its subsidiary, Shiv Shakti Oxalate Private Limited (SSOPL), which handles solvent recycling and recovery and printing chemicals.
Its product portfolio spans over 100 chemical products, including:
Pharmaceutical raw materials such as Methylene Chloride and Propylene Glycol
Solvents such as Acetone, Isopropyl Alcohol, Toluene and Methanol
Acids such as Acetic Acid and Formic Acid
Monomers such as Styrene Monomer and Vinyl Acetate Monomer
Speciality chemicals such as Acetonitrile and Acrylonitrile, along with nutraceuticals
During the last three fiscal years and the nine months ended 31 December 2025, the company supplied approximately 8.53 lakh MT of chemical products to over 3,000 customers. A sourcing network of 1,277 suppliers and warehouses at Bhiwandi, Maharashtra and Kandla, Gujarat, backs these operations. The SSOPL facility at MIDC Kurkumbh, Pune, carries an installed capacity of 15,000 MTPA for solvent recycling and recovery and 6,000 MTPA for printing chemicals.
Distribution generates nearly all the revenue. In Fiscal 2025, it accounted for 99.82% of the sale of products, with solvent recycling contributing the small balance in its first year. The mix began shifting in the nine months ended 31 December 2025, when distribution stood at 95.65%, solvent recycling and recovery at 3.52%, and printing chemicals at 0.82%.
Customers include distributors, traders, manufacturers and other industrial users across pharmaceuticals, agrochemicals, speciality chemicals, petrochemicals, automotive, paints and coatings, printing inks and packaging. The company supports procurement planning, consolidates demand, negotiates commercial terms and manages storage and logistics.
Products are procured from suppliers in India and from international markets, including the United States, the United Kingdom, Singapore, Canada, Hong Kong, Switzerland and France. As per the D&B Report cited in the DRHP, India ranks sixth worldwide in chemical production and third in Asia. Ujin Pharma operates as a distribution and processing participant within this ecosystem.
India's chemicals consumption market grew from USD 220 billion in FY 2023 to an estimated USD 295 billion in FY 2026, a CAGR of about 10.3%, according to the D&B Report cited in the DRHP. The same report projects USD 440 billion by FY 2030, a CAGR of about 10.5%.
The pharmaceutical-grade chemicals segment tells a similar story. It is projected to grow from ₹1,841 billion in FY 2025 to ₹2,742 billion by FY 2030, a CAGR of around 8.3%. India ranks as the third-largest pharmaceutical producer globally by volume, and its pharmaceutical market was valued at approximately USD 50 billion in FY 2023-24.
Key factors supporting the industry include:
Rising demand from pharmaceuticals, agrochemicals, construction, automotive and industrial manufacturing
Chemical exports of USD 25 to 30 billion annually, placing chemicals among India's top five merchandise export categories
Global supply chain diversification and stricter environmental norms in competing markets
Government initiatives supporting domestic API production and import substitution
Growing adoption of speciality chemicals in electronics, clean energy and electric mobility
Demand and pricing in chemicals still move with industrial cycles, currency movements and global trade conditions, which keep the industry sensitive to external shifts.
The table below presents the restated consolidated financial information of the company for the last three fiscal years and the nine months ended 31 December 2025.
| Period Ended (₹ crore) | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 699.31 | 615.82 | 483.50 | 395.67 |
| Total Income | 1,523.11 | 1,636.06 | 1,497.33 | 1,435.20 |
| Profit After Tax | 25.47 | 14.29 | 16.01 | 10.04 |
| EBITDA | 39.97 | 35.45 | 29.62 | 13.09 |
| Net Worth | 157.76 | 132.29 | 108.58 | 93.32 |
| Reserves and Surplus | 138.65 | 114.52 | 108.58 | 93.32 |
| Total Borrowing | 244.21 | 207.68 | 147.22 | 62.01 |
Profit after tax of ₹25.47 crore in the nine months ended 31 December 2025 exceeded the full-year figure for Fiscal 2025. As of the same date, the key performance indicators stood at a 2.64% EBITDA margin, a 1.62% PAT margin, a return on equity of 18.21%, a return on capital employed of 12.68% and a debt-to-equity ratio of 1.55.
Sourcing relationships with domestic and international suppliers, along with logistics coordination and inventory management, support continuity of supply across multiple end-use industries.
Over 100 products span solvents, acids, monomers, speciality chemicals, pharmaceutical raw materials and nutraceuticals. Many serve several industrial segments, which reduces dependence on any single category.
Warehouses and storage facilities in the logistics hubs of Bhiwandi and Kandla support the sourcing, storage and supply of chemical products across multiple regions in India.
The Kurkumbh facility adds solvent recycling and recovery and printing chemical production to the distribution platform, broadening the range of products and services the company can offer.
Promoters Jinesh Rasiklal Sheth and Umang Ketan Mehta each bring over two decades of experience in the chemical and pharmaceutical sectors. Revenue from operations rose from ₹14,257.61 million in Fiscal 2023 to ₹16,288.27 million in Fiscal 2025.
Distribution contributed 95.65% of the sales of products in the nine months ended 31 December 2025. Pressure on demand, pricing or supplier and customer relationships in this vertical would carry through to the whole business.
Methanol and Toluene together contributed 34.82% of revenue from the sale of products in the nine months ended 31 December 2025. A shift in demand or pricing for these two would affect revenue.
The top ten suppliers accounted for 48.10% of total purchases in Fiscal 2025. Imports from international suppliers stood at ₹4,140.12 million in the same year, which adds supply and currency risks.
Sales run on purchase orders rather than long-term contracts. A substantial portion flows through third-party traders and distributors, and a break in these relationships could dent revenue.
The planned shift towards integrated processing depends on scaling SSOPL and completing the two Altra investments. Delays or integration difficulties would slow that transition.
Legal proceedings involving the company, its subsidiary and its promoters remain outstanding. Adverse outcomes could hurt the reputation and financial position.
Before evaluating the Ujin Pharma IPO, investors may consider the following:
The position of the company as a chemical distributor with a value-added processing arm through SSOPL.
The issue structure, with a Fresh Issue of up to 11,869,100 equity shares and an OFS of up to 7,282,300 equity shares.
The proposed use of Net Proceeds towards the Altra investments of ₹61.72 crore and ₹21.64 crore, and debt repayment of ₹25 crore.
Historical financial performance, including thin distribution margins and the recent profit improvement.
The concentration of revenue in the distribution vertical and in products such as Methanol and Toluene.
Geographic concentration of domestic revenue in Maharashtra and Gujarat, as disclosed in the DRHP.
The growth outlook for chemicals consumption as per the D&B Report cited in the DRHP.
Outstanding legal proceedings and related party transactions are disclosed in the DRHP.
Disclaimer :
Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading